Correlation and prognostic value of serum soluble ICAM-1, beta-2 microglobulin, and IL-2αR levels in non-Hodgkin's lymphoma

Leukemia and Lymphoma

Volumn 33, Issue 5-6, 1999, Pages 551-558

  Perez Encinas M ^a,b   Quintas, Alfonso ^a   Bendaña, Angeles ^a   Rabuñal, María J ^a   Bello, José L ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b HOSPITAL GENERAL DE GALICIA   (Spain)

Author keywords

Beta 2 microglobulin; Non Hodgkin's lymphomas; Prognosis; sICAM 1; sIL 2 R

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BETA 2 MICROGLOBULIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2 RECEPTOR;

ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CANCER GRADING; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION FUNCTION; HUMAN; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS;

EID: 17144463678     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199909058459     Document Type: Article

References (29)

1. The International Non-Hodgkin's Lymphoma Prognostic Factors Proyect. (1993) A predictive model for aggressive non-Hodgkin's lymphoma. New England Journal of Medicine, 329, 987-994.
2. Swan, F. Jr., Velasquez, W.S., Tucker, S., Redman, J.R., Rodriguez, M.A., McLaughlin, P., Hagemeister, F.B., Cabanillas, F. (1989) A new serologic staging system for large-cell lymphomas based on initial beta 2-microglobulin and lactate dehydrogenase levels. Journal of Clinical Oncology, 7, 1518-1527.
3. Coiffier, B., Gisselbrecht, C., Vose, J.M., Tilly, H., Herbrecht, R., Bosly, A., Armitage, J.O., for the Groupe d'Etudes des Lymphomes Agressifs. (1991) Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that colud identify patients requiring a more intensive therapy. Journal of Clinical Oncology, 9, 211-219.
4. Rubin, L.A., Nelson, D.L. (1990) The soluble interleukin-2 receptor: biology, function, and clinical application. Annals of Internal Medicine, 113, 619-627.
5. Pizzolo, G., Chilosi, M., Semenzato, G. (1987) The soluble interleukin-2 receptor in haematological disorders. British Journal of Haematology, 67, 377-380.
6. Chilosi, M., Semenzato, G., Vinante, F., Menestrina, F., Piazzola, E., Focchiatti, V., Sabbioni, R., Zanotti, R., Pizzolo, G. (1989) Increased levels of soluble interleukin-2 receptor in non-Hodgkin lymphomas. Relationship with clinical, histologic and phenotypic features. American Journal of Clinical Pathology, 92, 186-191.
7. Pui, C-H., Ip, S.H., Kung, P., Dodge, R.K., Berard, C.W., Crist, W.M., Murphy, S.B. (1987). High serum interleukin-2 receptor levels are related to advanced disease and poor outcome in childhood non-Hodgkin's lymphoma. Blood, 70, 624-628.
8. Wagner, D.K., Kiwanuka, J., Edwards, B.K., Rubin, L.A., Nelson, D.L., Magrath, I.T. (1987) Soluble interleukin-2 receptor levels in patients with undifferentiated and lymphoblastic lymphomas: correlation with survival. Journal of Clinical Oncology, 5, 1262-1274.
9. Harrington, D.S., Patil, K., Lai, P.K., Yasuda, N.N., Armitage, J.O., Ip, S.H., Weisenburger, D.D., Linder, J., Purtilo, D.T. (1988) Soluble interleukin 2 receptors in patients with maligant lymphoma. Archives of Pathology and Laboratory Medicine, 112, 597-601.
10. Stasi, R., Zinzani, P.L., Galieni, P., Michele, V., Damasio, E., Dispensa, E., Dammacco, F., Papa, G., Tura, S. (1994) Prognostic value of serum IL-10 and soluble IL-2 receptor levels in aggressive non-Hodgkin's lymphoma. British Journal of Haematology, 88, 770-777.
11. Barak, V., Ginzburg, M., Kalickam, I., Polliack, A. (1992) Serum soluble interleukin-2 receptor levels are associated with clinical disease status and histopathological grade in non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Leukemia and Lymphoma, 7, 431-438.
12. Harabuchi, Y, Kataura, A., Imai, K. (1996) Circulating intercellular adhesion molecule-1 and its cellular expression in head and neck non-Hodgkin's lymphomas, includig lethal midline granuloma. Annals of Otology, Rhinology and Laryngology, 105, 634-642
13. Musolino, C., Alonci, A., Allegra, A., Spatari, G., Bellomo, G., Quartarone, M. (1996) Serum levels of soluble ICAM-1 in patients with malignant lymphoma in association with treatment response. British Journal of Haematology, 94, 580-581.
14. Christiansen, I., Gidlöf, C., Kälkner, K-M., Hagberg, H., Bennmarker, H., Tötterman, T. (1996) Elevated serum levels of soluble ICAM-1 in non-Hodgkin's lymphomas with tumour burden, disease activity and other prognostic markers. British Journal of Haematology, 92, 639-646.
15. Lister, T.A., Crowther, D., Sutcliffe, S.B., Glatstein, E., Canellos, G.P., Young, R.C., Rosemberg, S.A., Coltman, C.A., Tubiana, M. (1989) Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds Meeting. Journal of Clinical Oncology, 7, 1630-1636.
16. Lennert, K., Feller, A.C. (1991) Histopathologie des lymphomes malins non Hodgkiniens. 2 nd edn, pp. 20-57. Paris: Doin Editeurs.
17. Cavalli., F. (1991) Chemotherapy of non-Hodgkin's Lymphomas. Baillière's Clinical Haematology, 4, 157-180.
18. Gearing, A.J.H., Newman, W. (1993) Circulating adhesion molecules in disease. Immunology Today, 14, 506-512.
19. Heaney, M.L., Golde, D.W. (1996) Soluble cytokine receptors. Blood, 87, 847-857.
20. Smith, K,A. (1988) Interleukin-2: inception, impact, and implications. Science, 240, 1169-1176.
21. Salter, D.M., Krajewski, A.S., Sheehan, T., Turner, G., Guthbert, J.G., Mclen, A. (1989) Prognostic significance of activation and differentiation antigen expression in B-cell non-Hodgkin's lymphoma. Journal of Pathology, 159, 211-220.
22. Rubin, L.A., Kurman, C.C., Fritz, M.E., Biddison, W.E., Boutin, B., Yarchoan, R., Nelson, D.L. (1985) Soluble interleukin-2 receptors are released from activated human lymphoid cells in vitro. Journal of Immunology, 135, 3172-3177.
23. Carlos, T.M., Harlan, J.M. (1994) Leukocyte-endothelial adhesion molecules. Blood, 84, 2068-2101.
24. Freedman, A,S. (1993) Expression and function of adhesion receptors on normal B cells and B cell non-Hodgkin's lymphomas. Seminars in Hematology, 30, 318-28.
25. Stauder, R., Greil, R., Schulz, T.F., Thaler, J., Gattgringer, C., Radaskiewicz, T., Dierich, M.P., Huber, H. (1989) Expression of leukocyte function-associated antigen-and 7F7-antigen, and adhesion molecule related to intercellular adhesion molecule-1 (ICAM-1) in non-Hodgkin's lymphomas and leukemias: possible influence on growth patterns and leukemic behavior. Clinical and Experimental Immunology, 77, 234-238.
26. Terol, M-J., López-Guillermo, A., Bosch, F., Villamor, N., Cid, M-C., Rozman, C., Campo, E., Montserrat, E. (1998) Expression of the adhesion molecule ICAM-1 in non-Hodgkin's lymphoma: relationship with tumor dissemination and prognostic importance. Journal of Clinical Oncology, 16, 35-40.
27. Rothlein, R., Mainolfi, E.A., Czajkowski, M., Marlin, S.D. (1991) A form of circulating ICAM-1 in human serum. Journal of Immunology, 147, 3788-3793.
28. Seth, R., Raymond, F.D., Makgoba, M.W. (1991) Circulating ICAM-1 isoforms: diagnostic prospects for inflamatory and immune disorders. Lancet, 338, 83-84.
29. Litam, P., Swan, F., Cabanillas, F., Tucker, S.L., McLaughin, P., Hagemeister, F.B., Rodriguez, M.A., Velasquez, W.S. (1991) Prognostic value of serum β-2 microglobulin in low grade lymphoma. Annals of Internal Medicine, 114, 855-860.